Sun Pharma'ss Ankleshwar Unit: USFDA All-Clear, Hits 52-Week High

Photo:Representative Image

Shares of Sun Pharmaceutical Industries rose about 2%, hitting a 52-week high late on March 6, after the U.S. Food and Drug Administration (FDA) said it had granted full approval to Active Pharmaceutical Ingredient (API) from Ankleshwar Company). 

According to a report, the USFDA has classified this device as No Action (NAI), paving the way for factory production and export.

The highest level of the US FDA issued the NAI classification. Subject to regulatory compliance.

At 2.57 pm, Sun Pharma was trading at Rs 1,605.30 on the NSE.

Investors welcomed this development as the company was struggling with the negative effects of my work. It recently issued an import alert for Halol equipment and another compliance issue at its Mohali facility. These regulatory issues have weighed on the pharmaceutical company's earnings in the U.S. market.

Sun Pharma's share price has risen 29% in the past three months.

Sun Pharmaceutical Industries (Sun Pharma) is the fourth largest specialty pharmaceutical company. It has a worldwide sales value of $5.4 billion. Supported by 43 manufacturing facilities, we provide high-quality, affordable medicines trusted by healthcare professionals and patients in more than 100 countries worldwide.